- Advised on the successful blueprint grant application for $100,000.- Advised on development and regulatory strategy for diagnostic and therapeutic development.- Coached CEO and CSO on leadership and execution.

Pitch review and recommendations, emphasis in medical diagnostics and biopharma.

- Led a cross functional team of ~100 people in the development and commercialization of Guardant Health’s first tissue CGP test in 9mo from inception to commercial launch.- Obtained NYSDOH approval for operation in NY State.- Secured reimbursement approval through CMS (Palmetto GBA, LLC).

- Directed the development and validation of the Guardant360 TissueNext (LDT) product across all technical workstreams.- Grew the cross-functional technical team from 0 to ~60 people and established best practices for cross functional collaboration.

- Led a cross-functional team of ~60 people in the development of a high-throughput rtPCR-seq SARS-CoV-2 test under Emergency Use Authorization from the FDA and testing of over 100,000 patients. - Directed bioinformatics algorithm developers, analysts, and test developers developing new ctDNA biomarker functionality.- Directed a cross-functional team of ~20 people developing and maintaining the Guardant 360 and Omni liquid biopsy tests.

- Directed development of bioinformatics software submissions to the FDA.- Directed bioinformatics algorithm developers, analysts, and test developers developing new ctDNA biomarker functionality.- Established a new bioinformatics software architecture to enable the addition of new functionality.

- Managed cross-functional team of ~20 people developing the Guardant 360 CLIA & CAP compliant test. Preparing for FDA submission.- Managed bioinformatics algorithm developers, analysts, and test developers developing and maintain CLIA & CAP software.- Oversaw clinical reporting test 50,000+ patient results.

- Characterized the emergence of drug resistance in lung cancer patients using R.- Managed the implementation of the somatic variant caller using R.- Managed and implemented the automation of testing framework for bioinformatics pipeline.- Provided analytical support to Medical Affairs, Pharmaceutical Development, and Clinical Operations.

Developed a novel haplotype assembly method to assemble haplotypes in citrus hybrids using genetic diversity from the parental populations.Assembled and characterized the genetic diversity of Brassica rapa FPsc (A self-compatible Wisconsin Fast Plant).

Genetics:Incorporated genetic concept assessment into the genetics curriculum to assess learning outcomes.Established basic bioinformatics and command line tools in the curriculum.Developmental Genetics:Incorporated a development concept assessment into the development curriculum to assess learning outcomes.Migrated course material online (blackboard) to maximize educational value.Independent Study:Mentored post-bac students literature reviews on topics the reform U.S. health care to genetically modified organisms (GMOs).

As an advisor to Exogen Biotechnology, a start-up that studies DNA damage, I helped launch a successful crowd funded citizen science campaign that raised over $100k+ in crowd from 500+ funders on indiegogo. Through this campaign we hope to get a population level picture of DNA damage and understand the genetic, environmental, and life-style factors influence DNA damage and repair.https://www.indiegogo.com/projects/exogen-bio-how-damaged-is-your-dnaI also managed the design and production the sample collection kits mailed as part of the citizen science campaign, which can be seen here: http://exogenbio.com/product/one-time-scientist-pack/http://exogenbio.com/

I coordinated a team of 25 collaborators analyzing the genome and transcriptome of the first colonial choanoflagellate to be sequenced, Salpingoeca rosetta.

Thesis: The cellular and molecular basis of Salpinogoeca rosetta colony formation.Demonstrated the Salpinogoeca rosetta colony formation occurs through cell division.Purified the first colonial choanoflagellate for genome sequencing.Developed assays to quantify colony formation in response to the colony inducing prey bacterium.Characterized biochemical properties of colony triggering sphingolipid.Thesis research featured in New York Times:"In a Single-Cell Predator, Clues to the Animal Kingdom’s Birth"http://www.nytimes.com/2010/12/14/science/14creatures.html?_r=3&hpw

Elucidated the role of SPS1 in S. cerevisiae spore formation.• Determined SPS1 localization with immuno and fluorescent microscopy.• Purified antibody for immuno-precipitation and Western blot. • Applied genetics to characterize SPS1 interacting partners.• Mentored and managed undergraduate researchers and assistants.